07.11.2022
Roggwil, November 7, 2022 – In October, the tinniwell exceeded the 1,000 marks for the first time; it was exactly 1,085. That was an increase of 76% within a year.
The reason for this is that the number of patients with the long-COVID consequence tinnitus has increased explosively. The current mutation BQ.1.1 cannot be stopped by vaccinations and infections that have already been overcome. Experts expect the proportion of new infections to be 37% by the end of November. What is striking about this variant is that it behaves more aggressively than the mutations in summer. In practice, severe courses with up to 2 weeks bed confinement are observed.
For many tinnitus patients, this means that when they become infected, their tinnitus becomes louder, and the intensity can no longer be reconciled with life. Furthermore, the number of new patients who now get tinnitus and did not have any LONG-COVID consequences from previous COVID infections has increased significantly.
The management of Resaphene currently estimates the proportion of depressed patients at 30% and suicidal at 10%. An increase in the numbers is foreseeable due to the new infections.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668
a.rauterkus@resaphene.ch